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Pharmacokinetics in morbid obesity: influence of two bariatric surgery techniques on 
paracetamol and caffeine metabolism 
 
Purpose: To study the impact of the two most common bariatric surgery techniques on 
paracetamol pharmacokinetics (a marker of gastric emptying) and caffeine metabolism (a 
marker of liver function). 
Materials and methods: In the present prospective study, we studied 24 morbid obese 
patients before, at 4 weeks, and 6 months after having undergone sleeve gastrectomy (n=10) 
or Roux-en-Y gastric bypass (n=14). For comparative purposes, 28 healthy controls (14 
normal weight and 14 overweight) were also included in the study.  
Results: Paracetamol pharmacokinetics was altered in the obese participants leading to lower 
bioavailability. Bariatric surgery resulted in faster absorption and normalized pharmacokinetic 
parameters, prompting an increase in paracetamol bioavailability. No differences were found 
between surgical procedures. In the case of caffeine, the ratio paraxanthine/caffeine did not 
differ between morbid obese and healthy individuals. This ratio remained unmodified after 
surgery, indicating that liver function (assessed by cytochrome P450 1A2 activity) was 
unaffected by obesity or bariatric surgery. 
Conclusions: Paracetamol pharmacokinetics and caffeine plasma levels are altered in 
severely obese patients. The two studied bariatric surgical techniques normalize paracetamol 
oral bioavailability without impairing liver function (measured by cytochrome P450 1A2 
activity). 
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Introduction/Purpose 
Bariatric surgery involves a considerable alteration of the gastrointestinal tract because 
absorption is reduced and/or the absolute volume of the material that can be ingested at one 
time is restricted. Despite the beneficial effects of bariatric surgery on severely obese patients, 
surgical-derived alterations may have an impact on drug absorption and bioavailability that 
will ultimately lead to consequences regarding  dosage and administration [1]. To date, 
predicting the impact of bariatric surgery on drug pharmacokinetics constitutes a research 
challenge and it is considered to be drug-specific [2, 3].  
In this work, we report the impact of the two most common bariatric surgery 
techniques (laparoscopic Roux-en-Y gastric bypass (LRYGB) and Laparoscopic Sleeve 
Gastrectomy (LSG)) on paracetamol pharmacokinetics and caffeine metabolism. Paracetamol 
(acetaminophen), the most commonly used non-opioid analgesic, and caffeine were chosen to 
study how gastric emptying and liver function are altered by bariatric surgery, respectively. In 
the case of paracetamol, its absorption is negligible in the stomach but very rapid from the 
small intestine, the rate of absorption, therefore, depends on the rate of gastric emptying [4-7]. 
With respect to caffeine, the measurement of caffeine concentration in a single plasma sample 
has been proposed as a simple guide to evaluate liver function [8]. Moreover, the 
concentration of the molar ratio paraxanthine/caffeine (17X/137X) in plasma assessed by one 
sampling point taken 4 hours post dose is a straightforward, reliable, and relatively 
inexpensive estimate of cytochrome P450 1A2 (CYP1A2) activity [9] as it resembles 
systemic caffeine clearance [10].  
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Materials and Methods 
Subjects and study protocol 
A prospective cohort study was conducted in 24 patients with severe obesity planning to 
undergo bariatric surgery at Hospital del Mar (Barcelona, Spain). They were between 18 and 
55 years of age and met the 1991 bariatric surgery criteria of the National Institutes of Health 
[11]. Two different surgical procedures were considered: LRYGB (n=14) and LSG (n=10). 
Indication for the type of surgical procedure was based on clinical criteria and the consensus 
of the Bariatric Surgery Unit as previously described [12, 13]. Sample size was calculated to 
detect (1) a difference of at least a 30% in the depuration of the drugs used as biomarkers of a 
metabolic activity between obese subjects and controls, and (2) a 50% modification of 
paracetamol absorption velocity with a statistical power of 0.8. Using two-tailed tests and 
accepting an alpha risk of 0.05, a total number of 12 controls, 12 obese patients undergoing 
LSG and 12 obese patients undergoing LRYGB were considered necessary. 
We administered paracetamol and caffeine to obese patients before and at 4 weeks and 6 
months after two different bariatric surgery techniques. For comparative purposes, 
paracetamol pharmacokinetics and caffeine metabolism were also evaluated in 14 overweight 
subjects and 14 normal weight control subjects. Protocol appointments included 
measurements of weight, waist and hip circumferences, as well as pharmacokinetic 
measurements. 
Participants were instructed not to consume ethanol, caffeine, or xanthine-related products 
(e.g. coffee, tea, colas, chocolate) for 2 days before the study sessions. Subjects were 
excluded if they were taking medication known to induce or inhibit CYP enzymes or had a 
history of hypersensitivity to drugs used in the study. After overnight fasting and baseline 
procedures, each subject received a modified Karolinska cocktail [14, 15] including 5 drugs: 
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dextromethorphan (Romilar®, 30 mg), losartan (Cozaar®, 12.5 mg), omeprazole (Losec®, 20 
mg), caffeine (65 mg), and paracetamol (Panadol® Extra, containing 500 mg of paracetamol 
and 65 mg of caffeine). Dextromethorphan (30 mg) was self-administered the night before 
each session. Losartan (25 mg), paracetamol-caffeine (500 mg and 65 mg) were administered 
between 08:00 and 08:15 hours and omeprazole (20 mg) one hour later.  
Blood samples (3 mL each) were taken at: 0, 15, 30, 60 minutes and 2, 3 and 4 hours after 
oral cocktail administration for paracetamol analysis and at 0 and 4 hours for caffeine 
analysis. Urine was collected overnight (0-8 hours) after dextromethorphan and during the 
experimental session. For comparative purposes, 14 overweight subjects (BMI 25-30 kg/m
2
), 
and 14 normal weight control subjects (BMI<25) were additionally included in the study and 
also received the same modified Karolinska cocktail. This procedure was performed a single 
time in healthy volunteers (overweight and normal weight control subjects) and three times is 
MO patients: before surgery, 4 weeks after surgery, and 6 months after surgery.  
All MO subjects were informed of the surgical risks and benefits and signed their 
informed consent for the surgical procedure. All subjects also signed an informed consent 
document for study participation.  
Surgical techniques 
The LRYGB technique involved a 150-cm antecolic Roux limb with 25-mm circular 
pouch-jejunostomy and exclusion of 50 cm of the proximal jejunum. In LSG, the longitudinal 
resection of the stomach from the angle of His to approximately 5 cm proximal to the pylorus 
was performed using a 35 French bougie inserted along the lesser curvature. All operations 
were performed by the same team of surgeons. 
Chemicals, Instrumentation, and Analytical Methods 
5 
 
All chemical reagents were of the highest grade available. Paracetamol, its internal 
standard metacetamol, and caffeine, paraxanthine and the internal standard diphylline, were 
from Sigma-Aldrich Quimica SA (Madrid, Spain). Plasma concentrations of all compounds 
were determined using a 1090 II high performance liquid chromatography modular system 
coupled to a 1100 Series UV detector (Agilent, Palo Alto, CA, USA). Caffeine and 
paraxanthine were extracted and analyzed following  previously published methodology [16]. 
In a similar way, the simultaneous analysis of paracetamol and metacetamol in plasma was 
performed as reported elsewhere [17]. 
Pharmacokinetics 
Data were fitted to one compartmental pharmacokinetic model with first-order 
elimination using GraphPad Prism (GraphPad Software, CA, USA, version 5.03 for 
Windows) and PKSolver (a freely available add-in program for Microsoft Excel). For further 
details, see the Supplementary Material.  
Statistics 
A descriptive analysis of both the baseline sociodemographic characteristics and the 
clinical parameters is given by the mean and the standard deviation for continuous variables 
and the absolute and relative frequencies for categorical ones. To compare the different 
weight categories (normal weight, overweight, and morbid obese) with respect to clinical 
parameters and plasma pharmacokinetic parameters of paracetamol, one-way ANOVA 
models were used. Statistical significance was set at 0.05. The plasma pharmacokinetic 
parameters of paracetamol were analyzed as a function of time and treatment for obesity. For 
this purpose, repeated measures ANOVA models for the differences from baseline at sessions 
2 and 3 were fitted for all parameters including time, treatment, and the interaction of both as 
factors. A detailed description of the statistical analyses can be found in the Supplementary 
Material.  
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Results 
Baseline characteristics 
Anthropometric and biochemical parameters 
The baseline characteristics of the 24 obese patients were compared with those of the 
normal weight (n=14) and overweight (n=14) volunteers. In our sample, the mean age of the 
obese subjects was higher than the mean age of normal and overweight ones. The obese group 
had a higher SBP compared to the normal and overweight groups. No statistically significant 
differences were found in DBP. The heart rate (HR) of obese individuals was higher than 
normal weight volunteers (Table 1).  
Paracetamol pharmacokinetics 
Paracetamol pharmacokinetic parameters in plasma following the oral intake of 500 
mg of paracetamol (administered as a modified Karolinska cocktail) are summarized in Table 
2 and plasma concentration–time profile is depicted in Figure 1. The maximum plasma 
concentration of paracetamol (Cmax) and its corresponding area under the curve (AUC) was 
significantly lower in morbid obese than in normal and overweight individuals (p<0.05). 
Paracetamol elimination half-life (t1/2), time to reach Cmax (tmax), and elimination rate constant 
(Ke) did not differ significantly among groups. The apparent volume of distribution (VD/F) 
and metabolic clearance (CL/F) were greater in morbid obese than in normal and overweight 
subjects (p<0.005). However, after the individual correction for total body weight, neither 
VD/F (VD/F.Weight) nor CL/F (CL/F.Weight) differed significantly among groups. These 
results are in agreement with data described in the literature [18].  
 
Paraxanthine/caffeine (17X/137X) plasma levels 
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Before surgery (Session 1) the obese group had lower concentrations of caffeine and 
paraxanthine compared to the normal and overweight groups (p<0.05). However, the ratio 
paraxanthine/caffeine did not differ significantly among groups (Table 3). 
 
Comparative effects between surgical procedures (LRYGR and LSG) 
Clinical outcomes 
There were no serious perioperative complications related to either bariatric surgery or 
to secondary effects of the drugs used in the study. There was no mortality in either technique. 
Weight and BMI  
Figure 2 shows the evolution of total body weight and BMI at 1 and 6 months after 
bariatric surgery (session 2 and 3, respectively). As expected, four weeks after the 
intervention (session 2) a considerable reduction of body weight (mean loss of -17 kg) was 
observed (p<0.001).This reduction continued over time and a mean loss of -32 kg was 
registered six months after surgery (Session 3) (p<0.001). A similar trend was observed in 
BMI. Despite finding marked differences among sessions none were observed between 
surgical procedures with respect to changes from baseline (p=0.999) (Figure 2). 
Comparison of paracetamol pharmacokinetic parameters between surgical procedures 
No significant differences were found between LRYGB and LSG for any 
pharmacokinetic variable. Following bariatric surgery, an increase was observed in AUC0-4h 
and AUC0-inf, whereas a decrease was found in VD/F and CL/F. When body weight was taken 
into account, the VD/F did not differ significantly among sessions. Cmax did not change either 
among sessions, probably due to low statistical power (Supplementary Table 1).  
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Comparison of plasma caffeine and paraxanthine concentrations between surgical 
procedures 
No significant differences were found between LRYGB and LSG in plasma caffeine 
(p=0.616) and paraxanthine concentrations (p=0.903). In a similar way, the ratio 
paraxanthine/caffeine did not differ significantly between surgical techniques. 
Consequences of bariatric surgery: between sessions 1, 2 and 3 
Paracetamol pharmacokinetic outcomes  
Paracetamol pharmacokinetic parameters changed as a consequence of bariatric 
surgery (Figure 3). An increase was observed in Cmax, AUC0-4h, and AUC0-inf, whereas a 
significant decrease was observed in VD/F and CL/F. The assessment of relative 
bioavailability in sessions 2 and 3 compared with session 1 showed an increase in oral 
bioavailability in Cmax of 30% and 38%, respectively, and an increase in AUC0-inf of 47% and 
41%, respectively. Distribution volume values of paracetamol did not present significant 
differences among all sessions after normalization with body weight. Additionally, non-
relevant differences in plasma clearance values of paracetamol, when normalized by body 
weight before and after 6 months of bariatric surgery, were observed. Tmax values decreased 
from 1 hour (before surgery) to 0.5 hours (6 months after surgery), indicating a faster 
absorption as a consequence of the surgical intervention (Table 4). 
Caffeine and paraxanthine plasma concentrations 
Neither caffeine plasma concentrations nor the ratio paraxanthine/caffeine at 4 hours after a 
single oral administration of 65 mg of caffeine differed significantly among sessions. 
However, in the case of paraxanthine, the plasma concentrations diminished at session 2, 
becoming normalized at session 3 (Table 5).    
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Discussion 
In the present study we report that (1) paracetamol pharmacokinetics and caffeine 
plasma levels are altered in severely obese patients and (2) that two bariatric surgical 
techniques modify paracetamol oral bioavailability without impairing liver function 
(measured by CYP1A2 activity).   
We have studied the impact of the two most commonly used bariatric surgery 
techniques (gastric bypass and sleeve gastrectomy) with regard to paracetamol 
pharmacokinetics (the most commonly used analgesic drug with a well-known 
pharmacokinetic profile) and caffeine metabolism (the most frequently consumed 
psychostimulant worldwide) [19]. It is important to evaluate paracetamol pharmacokinetics in 
obese subjects in order to determine whether the recommended dose for individuals with 
normal weight can be extrapolated to obese patients.  
We found that paracetamol pharmacokinetics is altered in severe obesity. Morbid 
obese patients had a higher VD and CL, and lower AUC and Cmax values, compared to normal 
weight and overweight individuals. When the apparent distribution volume and clearance 
were normalized by body weight, no differences were found, indicating that body weight was 
responsible for the apparent increase of these parameters. On the basis of our results, the 
recommended therapeutic doses of paracetamol are safe for obese individuals, as the plasma 
levels that are reached after an oral intake are lower than the ones achieved in normal and 
overweight individuals. In the case of therapeutic failure, the possibility of increasing the dose 
of paracetamol in obese patients in order to achieve plasma levels similar to those attained in 
normal weight individuals could be evaluated. Current guidelines for paracetamol dosage in 
obese patients recommend adjusting the dose of paracetamol using the ideal body weight [20]. 
Interestingly, after undergoing bariatric surgery, VD and CL values decreased and AUC and 
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Cmax values increased, indicating a normalization of paracetamol pharmacokinetics. As an 
example, before surgery AUC0-4h was 32% lower in obese subjects than in normal weight 
individuals, but 6 months after surgery it was only 4% less. Moreover, Tmax value decreased 
from 1 hour (before surgery) to 30 minutes (6 months post-surgery). The normalization of the 
pharmacokinetic parameters can be explained by the considerable weight loss caused by 
bariatric surgery, whereas the decrease in Tmax is compatible with the consequence of the 
surgical procedure. Indeed, bariatric surgery leads to a faster entry of paracetamol to the 
intestine and its consequent absorption, as paracetamol absorption occurs mainly in the small 
intestine and strictly depends on the rate of gastric emptying [4, 6].  
Taken together, these results indicate that after bariatric surgery paracetamol 
absorption takes place faster (earlier Tmax values), reaches higher plasma concentrations 
(Cmax), and results in a higher bioavailability (AUC) in comparison with the same individuals 
before surgery. It is noteworthy that normalization of paracetamol plasma levels was observed 
as a consequence of bariatric surgery as the AUC at 6 months after surgery did not differ from 
the bioavailability in normal weight individuals. On the basis of these results, we postulate 
that the increase in paracetamol oral bioavailability could be explained by a higher fraction of 
paracetamol absorbed across the gut wall (greater bioavailability) rather than by a higher rate 
of absorption. Indeed, when we employed the Cmax/AUC0-inf ratio as an indicator of the rate of 
absorption [21, 22] we did not observe an increase in this parameter related to bariatric 
surgery (Table 4). 
In the case of caffeine, obese patients had lower caffeine and paraxanthine plasma 
concentrations in comparison with normal and overweight individuals. This can be explained 
by the fact that the volume of distribution is markedly increased in obese subjects [23]. There 
were no baseline differences in the ratio paraxanthine/caffeine (17X/137X). Bariatric surgery 
did not alter either caffeine or the paraxanthine/caffeine ratio, indicating that CYP1A2 activity 
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was unimpaired. A decrease in paraxanthine concentrations was observed 4 weeks after 
surgery but this was normalized at 6 months. 
One of the strengths of the present study stems from its design, in which each subject 
acts as the corresponding control thus minimizing the influence of confounding variables and 
interindividual variability. Moreover, the inclusion of normal weight and overweight subjects 
allows the comparison of the values from morbid obese subjects with those of healthy ones. 
The present study has some limitations. Standard therapeutic doses of drugs were 
administered to study participants irrespective of their BMI. Another approach would be to 
adjust drug dosing by body weight. We believe that conclusions achieved would be the same 
following both dosing approaches. Although a prospective design was performed and we 
evaluated effects of bariatric surgery up to 6 months after surgery, we did not, however, 
assess the long-term effects when, according to the literature, some patients experience weight 
regain [24, 25]. Neither did we include extremely morbid obese patients (BMI>50 or 60), 
nevertheless, the characteristics of our subjects concur with those in the vast majority of the 
articles published on bariatric surgery. Finally, it is worth mentioning that the Karolinska 
cocktail includes five drugs and this paper only focused on paracetamol and caffeine with a 
particular emphasis on their metabolism. The other drugs included in the cocktail 
(dextromethorphan, losartan, and omeprazole) and the impact of bariatric surgery on the 
activity of CYP isoforms are beyond the scope of this work and will be covered in a 
forthcoming article.  
Conclusions 
Paracetamol pharmacokinetics was altered in MO patients, presenting a higher 
apparent distribution volume and clearance, reaching lower plasma concentrations, and 
leading to lower bioavailability. As a consequence of bariatric surgery, absorption was faster 
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and the previous parameters were normalized without differences being observed between 
both surgical procedures. In the case of caffeine, the paraxanthine/caffeine ratio was 
employed to study liver function. No differences were found in this ratio between obese 
patients and healthy individuals. Moreover, it was not altered by bariatric surgery, indicating 
that these bariatric techniques do not impair liver function assessed by CYP1A2 activity. 
 
Conflict of interest disclosure: The authors declare that they have no conflict of interest. 
Ethical statement: All procedures performed in the study involving human participants were 
in accordance with the ethical standards of the institutional and/or national research 
committee and with the 1964 Helsinki declaration and its later amendments or comparable 
ethical standards.  
Consent statement: Informed consent was obtained from all individual participants included 
in the study. 
 
  
13 
 
References 
1. Stein J, Stier C, Raab H, Weiner R. Review article: the nutritional and 
pharmacological consequences of obesity surgery. Aliment Pharmacol Ther. 2014;40(6):582-
609. 
2. Greenblatt HK, Greenblatt DJ. Altered Drug Disposition Following Bariatric Surgery: 
A Research Challenge. Clin Pharmacokinet. 2015;54(6):573-9. 
3. Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following 
bariatric surgery and its theoretical implications. Obes Rev. 2010;11(1):41-50. 
4. Prescott LF. Kinetics and metabolism of paracetamol and phenacetin. Brit J Clin 
Pharmacol. 1980;10(S2):291S-8S. 
5. Raffa RB, Pergolizzi JV, Taylor R, Decker JF, Patrick JT. Acetaminophen 
(Paracetamol) Oral Absorption and Clinical Influences. Pain Practice. 2014;14(7):668-77. 
6. Heading RC, Nimmo J, Prescott LF, Tothill P. The dependence of paracetamol 
absorption on the rate of gastric emptying. Br J Pharmacol. 1973;47(2):415-21. 
7. Bartholomé R, Salden B, Vrolijk MF, Troost FJ, Masclee A, Bast A, et al. 
Paracetamol as a Post Prandial Marker for Gastric Emptying, A Food-Drug Interaction on 
Absorption. PLoS ONE. 2015;10(9):e0136618. 
8. Renner E, Wietholtz H, Huguenin P, Arnaud MJ, Preisig R. Caffeine: A Model 
Compound for Measuring Liver Function. Hepatology. 1984;4(1):38-46. 
9. Carrillo JA, Christensen M, Ramos SI, Alm C, Dahl M-L, Benítez J, et al. Evaluation 
of Caffeine as an In Vivo Probe for CYP1A2 Using Measurements in Plasma, Saliva, and 
Urine. Ther Drug Monit. 2000;22(4):409-17. 
10. Doude van Troostwijk LJAE, Koopmans RP, Guchelaar H-J. Two novel methods for 
the determination of CYP1A2 activity using the paraxanthine/caffeine ratio. Fundam Clin 
Pharmacol. 2003;17(3):355-62. 
14 
 
11. Hubbard V, Hall H. National Institutes of Health Consensus Development Conference 
Draft statement on gastrointestinal surgery for severe obesity. Obes Surg. 1991;1(3):257-65. 
12. Benaiges D, Goday A, Pedro-Botet J, Mas A, Chillaron JJ, Flores-Le Roux JA. 
Bariatric surgery: to whom and when? Minerva Endocrinol. 2015 Jun;40(2):119-28. 
13. Vidal P, Ramón JM, Goday A, Benaiges D, Trillo L, Parri A, et al. Laparoscopic 
Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy as a Definitive Surgical Procedure 
for Morbid Obesity. Mid-Term Results. Obes Surg. 2013;23(3):292-9. 
14. Christensen M, Andersson K, Dalén P, Mirghani RA, Muirhead GJ, Nordmark A, et 
al. The karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin 
Pharmacol Ther. 2003;73(6):517-28. 
15. Hu OY-P, Tang H-S, Lane H-Y, Chang W-H, Hu T-M. Novel Single-Point Plasma or 
Saliva Dextromethorphan Method for Determining CYP2D6 Activity. J Pharmacol Exp Ther. 
1998;285(3):955-60. 
16. Carbó M, Segura J, De la Torre R, Badenas JM, Camí J. Effect of quinolones on 
caffeine disposition. Clin Pharmacol Ther. 1989;45(3):234-40. 
17. Farré M, Roset P, Pascual J, Mas M, Sanagustín J, Menoyo E, et al. Estudio de la 
biodisponibilidad comparativa de la asociación de paracetamol y codeína (Gelocatil Codeína) 
frente a un preparado de referencia. Dolor. 1999;14:163-71. 
18. Abernethy DR, Divoll M, Greenblatt DJ, Ameer B. Obesity, sex, and acetaminophen 
disposition. Clin Pharmacol Ther. 1982;31(6):783-90. 
19. Cappelletti S, Daria P, Sani G, Aromatario M. Caffeine: Cognitive and Physical 
Performance Enhancer or Psychoactive Drug? Curr Neuropharmacol. 2015;13(1):71-88. 
20. De Baerdemaeker LE, Mortier EP, Struys MM. Pharmacokinetics in obese patients. 
Contin Educ Anaesth Crit Care Pain. 2004;4(5):152-5. 
15 
 
21. Portolés A, Puerro M, Terleira A, Rodrı́guez A, Caturla M-C, Fernández N, et al. A 
new high-absorption-rate Paracetamol 500-mg formulation: a comparative bioavailability 
study in healthy volunteers. Curr Ther Res. 2003;64(7):401-11. 
22. Endrenyi L, Tothfalusi L. Metrics for the evaluation of bioequivalence of modified-
release formulations. AAPS J. 2012;14(4):813-9. 
23. Abernethy DR, Todd EL, Schwartz JB. Caffeine disposition in obesity. Br J Clin 
Pharmacol. 1985;20(1):61-6. 
24. Courcoulas AP, Christian NJ, Belle SH, Berk PD, Flum DR, Garcia L, et al. Weight 
Change and Health Outcomes at Three Years After Bariatric Surgery Among Patients with 
Severe Obesity. JAMA. 2013;310(22):2416-25. 
25. Kushner RF, Sorensen KW. Prevention of Weight Regain Following Bariatric 
Surgery. Curr Obes Rep. 2015;4(2):198-206. 
 
 
  
16 
 
Figure legends 
Figure 1. Basal (Session 1) time-course plasma concentrations of paracetamol after the oral 
administration of 500 mg of paracetamol (administered as a modified Karolinska cocktail) to 
normal weight (n=14), overweight (n=14) and morbid obese (n=24) volunteers. Data are 
expressed mean ± SEM.  
Figure 2. Evolution of body weight (A) and body mass index (BMI; B) before surgery 
(session 1), four weeks post-surgery (session 2), and six months post-surgery (session3). 
Values are expressed as mean ± SD. 
Figure 3. Time-course plasma concentrations of paracetamol following the oral 
administration of 500 mg of paracetamol (administered as a modified Karolinska cocktail) in 
morbid obese volunteers before (session 1), one month (session 2), and six months (session 3) 
after bariatric surgery. Data are expressed mean ± SEM.  
  
17 
 
Tables  
Table 1. Sociodemographic baseline characteristics and basal clinical parameters of the 24 
patients, compared with normal weight and overweight volunteers. Data are expressed as 
mean ± SD. *Significant differences between the three subject groups. NS: Not significant 
 Normal weight Overweight Obese *Differences 
N 14 14 24 - 
Age (years) 32.2 ± 5.6 34.6 ± 6.6 41.4 ± 8.8 *Normal, overweight < obese 
Females 12 14 24 - 
Males 2 0 0 - 
Smokers 36% 29% 38% - 
Height (cm) 167 ± 9 161 ± 5 161 ± 9 - 
Weight (kg) 64.4 ± 7.6 71.4 ± 5.4 111.6 ± 15.0 *Normal < overweight < obese 
BMI (kg/m
2
) 23.0 ± 1.2 27.6 ± 1.1 43.1 ± 3.4 *Normal < overweight < obese 
SBP (mm Hg) 107.3 ± 7.6 114.9 ± 9.9  124.3 ± 12.3 *Normal < overweight < obese 
DBP (mm Hg) 66.6 ± 6.2 65.6 ± 6.9 68.8 ± 10.7 NS 
HR (bpm) 61.4 ± 8.5 65.9 ± 7.0 68.4 ± 8.5 *Normal < obese, overweight 
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Table 2. Plasma pharmacokinetic parameters of paracetamol in normal weight (n=14), 
overweight (n=14), and obese (n=24) volunteers after a single oral administration of 
modified Karolinska cocktail containing 500 mg of paracetamol. Data are expressed as mean 
± SD with the only exception of tmax, where median and minimum–maximum ranges are given. 
*Significant differences between the three subject groups. NS: Not significant. 
 Normal 
weight 
Overweight Obese *Differences 
Cmax (µg/mL) 7.0 ± 1.7 7.6 ± 1.8 5.4 ± 2.3 *Normal, overweight > obese 
AUC0-4h (µg·h/mL) 16.4 ± 3.3 16.9 ± 3.9 11.2 ± 4.7 *Normal, overweight > obese 
AUC0-inf (µg·h/mL) 24.4 ± 5.6 23.8 ± 5.5  15.5 ± 6.7 *Normal, overweight > obese 
Ke (h
-1
) 0.36 ± 0.09 0.37 ± 0.06 0.42 ± 0.11 NS 
t1/2 (h) 2.07 ± 0.58  1.91 ± 0.36 1.76 ± 0.43 NS 
tmax (h) 1 (0.5-3) 1 (0.5-2) 1 (0.5-2) NS 
VD/F (L) 62.3 ± 16.7 60.0 ± 13.8 90.8 ± 26.1 *Normal, overweight < obese 
VD/F.Weight (L/kg) 0.96 ± 0.20 0.83 ± 0.15 0.81 ± 0.20 NS 
CL/F (L/h) 21.5 ± 4.6 22.3 ± 5.7 38.7 ± 17.9 *Normal, overweight < obese 
CL/F.Weight (L/h/kg) 0.33 ± 0.07 0.31 ± 0.06 0.35 ± 0.17 NS 
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Table 3. Caffeine and paraxanthine plasma concentrations in normal weight (n=14), 
overweight (n=14), and obese (n=24) volunteers 4 hours after a single oral  administration of 
modified Karolinska cocktail containing 60 mg of caffeine. Data are expressed as mean ± SD. 
*Significant differences between the three subject groups. NS: Not significant 
 Normal weight Overweight Obese *Differences 
Caffeine (ng/mL) 0.32 ± 0.16 0.36 ± 0.18 0.23 ± 0.11 *Normal, overweight > obese 
Paraxanthine (ng/mL) 0.11 ± 0.04 0.10 ± 0.03 0.08 ± 0.03 *Normal, overweight > obese 
17X/137X (molar ratio) 0.40 ± 0.12 0.37 ± 0.18 0.42 ± 0.21 NS 
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Table 4. Plasma pharmacokinetic parameters of paracetamol following the oral 
administration of 500 mg of paracetamol in obese patients (n=24) before (session 1), one 
month (session 2), and six months (session 3) after undergoing bariatric surgery. Data are 
expressed as mean ± SD with the only exception of tmax, where median and minimum–
maximum ranges are given. *Significant differences between the three sessions in the morbid 
obese subjects. NS: Not significant. 
 Session 1 Session 2 Session 3 *Differences 
Cmax (µg/mL) 5.36 ± 2.29 6.99 ± 2.75 7.39 ± 2.60 S1 < S2, S3 
AUC0-4h (µg·h/mL) 11.2 ± 4.7 15.3 ± 5.1 15.8 ± 3.6 S1 < S2, S3 
AUC0-inf (µg·h/mL) 15.5 ± 6.7 22.8 ± 8.5 21.8 ± 6.5 S1 < S2, S3 
ke (h
-1
) 0.42 ± 0.11 0.34 ± 0.08 0.38 ± 0.09 S1 > S2 < S3 
t1/2 (h) 1.76 ± 0.43 2.17 ± 0.47 1.91 ± 0.42 S1 < S2 > S3 
tmax (h) 1 (0.5-2.0) 1 (0.5-2.0) 0.5 (0.25-1.0) S2, S1 > S3 
VD/F (L) 90.8 ± 26.1 75.2 ± 23.0 65.4 ± 11.3 S1 > S2, S3 
VD/F.Weight (L/kg) 0.81 ± 0.20 0.79 ± 0.18 0.83 ± 0.13 NS 
CL/F (L/h) 38.7 ± 17.9 25.8 ± 12.9 25.1 ± 8.1 S1 > S2, S3 
CL/F.Weight (L/h/kg) 0.35 ± 0.17 0.27 ± 0.12 0.32 ± 0.11 S1 > S2 < S3 
Relative bioavailability (Frel) 100 160.8 ± 49.3 149.6 ± 39.8 S1 < S2, S3 
Cmax/AUC0-inf (h
-1
) 0.36 ± 0.09 0.32 ± 0.10 0.36 ± 0.14 NS 
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Table 5. Caffeine and paraxanthine plasma concentrations in obese patients (n=24) 
before (session 1), one month (session 2), and six months (session 3) after undergoing 
bariatric surgery. Concentrations were determined 4 hours after a single oral administration 
of modified Karolinska cocktail containing 65 mg of caffeine. Data are expressed as mean ± 
SD. *Significant differences between the three sessions in the morbid obese subjects. NS: Not 
significant. 
 Session 1 Session 2 Session 3 *Differences 
Caffeine (ng/mL) 0.21 ± 0.09 0.21 ± 0.08 0.24 ± 0.12 NS 
Paraxanthine (ng/mL) 0.07 ± 0.03 0.05 ± 0.02 0.08 ± 0.04 S1>S2<S3 
Paraxanthine/Caffeine 0.44 ± 0.22 0.38 ± 0.35 0.48 ± 0.33 NS 
 
 
 
